Hester Biosciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022
November 04, 2022 at 06:54 am
Share
Hester Biosciences Limited reported earnings results for the second quarter and six months ended September 30, 2022. For the second quarter, the company reported sales was INR 731.53 million compared to INR 626.62 million a year ago. Revenue was INR 776.02 million compared to INR 640.86 million a year ago. Net income was INR 69.42 million compared to INR 106.23 million a year ago. Basic earnings per share from continuing operations was INR 7.77 compared to INR 13.08 a year ago.
For the six months, sales was INR 1,238.48 million compared to INR 1,228.48 million a year ago. Revenue was INR 1,314.2 million compared to INR 1,266.2 million a year ago. Net income was INR 109.1 million compared to INR 231.13 million a year ago. Basic earnings per share from continuing operations was INR 11.95 compared to INR 26.03 a year ago.
Hester Biosciences Limited is an India-based animal healthcare company. The Company is engaged in providing vaccines, health products and diagnostic laboratory services. The Company operates through four segments: Poultry Healthcare, Animal Healthcare, Petcare, and Others. The Animal Healthcare vaccines include Goat Pox Vaccine, Live Brucella, PPR Vaccine - Nigerian 75/1, and PPR Vaccine - Sungri/96. Its Poultry Healthcare products include Gumboro I, Gumboro I +, Inactivated Chick ND, Inactivated Coryza, Inactivated Coryza+, Inactivated EDS, Inactivated FC3, Inactivated FC4, Inactivated IB, Inactivated IB+, Inactivated IB-H52, Inactivated IBD, Inactivated IBD ND, Inactivated IBD ND EDS, Inactivated ND IB, Inactivated Pullet ND, Live B1, Live B1 M48, Live FP, Live H120, Live Las, Live Las Mas, Live M48, Live R2B, Live S-One, MD-Bivalent HVT+SB1, MD-HVT (FD), and Thermostable ND. Its Petcare products include Cefshot Tazo Injection, Hestacef CV, Hestacef DS, Hestaflam Tablet and Hestaliv.
HESTER BIOSCIENCES LIMITED 
